Previous 10 | Next 10 |
- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first extracellular vesicle product candidate EDP2939 in psoriasis anticipated in 2H 2023 ȁ...
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that Simba Gill, Ph.D., Chief Executive O...
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today presented biomarker data demonstrating the broad a...
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that the Company will participate in a f...
Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Conference Call August 11, 2022 07:30 ET Company Participants Kendra Sweeney - Investor Relations Simba Gill - Chief Executive Officer Ara Darzi - Chairman Conference Call Participants Chris Howerton - J...
Image source: The Motley Fool. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q2 2022 Earnings Call Aug 11, 2022 , 7:30 a.m. ET Operator Continue reading For further details see: Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Call Transcript
Evelo Biosciences ( NASDAQ: EVLO ) announced the succession plan for Simba Gill, to transition from his roles as CEO and President to the role of Chair of the Board and return to Flagship Pioneering to help launch, grow, and guide bioplatform companies. The company bo...
Evelo Biosciences press release ( NASDAQ: EVLO ): Q2 GAAP EPS of -$0.40 beats by $0.03 . As of June 30, 2022, cash and cash equivalents were $92.0M, as compared to cash and cash equivalents of $68.4M as of December 31, 2021. For further details see: Evelo Bio...
– Simba Gill to transition to Chair of the Board of Directors – – Lord Ara Darzi will become Lead Independent Director – – Board has retained Spencer Stuart for Chief Executive Officer search – CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEW...
– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end – – Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 – – Phase 2 data for EDP2939 in psoriasis expected in 2H 20...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
NASDAQ Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...